Natera (NASDAQ:NTRA) Stock Price Expected to Rise, BTIG Research Analyst Says

Natera (NASDAQ:NTRA) had its price objective lifted by equities researchers at BTIG Research from $250.00 to $270.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. BTIG Research’s price target indicates a potential upside of 15.01% from the stock’s current price.

A number of other research analysts also recently weighed in on NTRA. Piper Sandler restated an “overweight” rating and set a $249.00 price objective on shares of Natera in a research report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. JPMorgan Chase & Co. boosted their price target on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Evercore restated an “outperform” rating and set a $270.00 price objective on shares of Natera in a research report on Friday, May 8th. Finally, Wells Fargo & Company upped their price target on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $257.71.

Natera Stock Up 2.6%

Shares of NASDAQ:NTRA traded up $5.96 on Tuesday, hitting $234.76. 1,870,530 shares of the company traded hands, compared to its average volume of 1,329,242. Natera has a 52 week low of $131.81 and a 52 week high of $256.36. The company has a market cap of $33.62 billion, a PE ratio of -144.02 and a beta of 1.56. The stock has a 50 day simple moving average of $208.72 and a 200-day simple moving average of $215.33.

Insider Activity

In related news, Director Rowan E. Chapman sold 2,964 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the completion of the transaction, the director owned 3,124 shares in the company, valued at $677,220.72. The trade was a 48.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the transaction, the director directly owned 6,183 shares in the company, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 162,342 shares of company stock worth $35,283,396 in the last three months. Corporate insiders own 5.05% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently added to or reduced their stakes in the stock. Horizon Investments LLC increased its position in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC boosted its holdings in shares of Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares during the period. Savvy Advisors Inc. grew its stake in Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after purchasing an additional 46 shares in the last quarter. Parallel Advisors LLC increased its holdings in Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after purchasing an additional 47 shares during the period. Finally, First Horizon Corp raised its position in Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 51 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.